Dosing and uses of Lamisil AT topical (terbinafine topical)
Adult dosage forms and strengths
cream/topical solution
- 1%
Tinea Pedis
Apply to affected area BID until significant clinical improvement (no more than 4 weeks)
Tinea Corporis & Cruris
Apply qDay x1 week (no more than 4 weeks)
Pediatric dosage forms and strengths
Not FDA approved for peds
Lamisil AT topical (terbinafine topical) adverse (side) effects
1-10%
Burning
Contact dermatitis
Dryness
Exfoliation
Irritation
Pruritus
Rash
Irritation
Stinging
Warnings
Contraindications
Hypersensitivity
Not for oral, intravaginal, ophthalmic use
Pregnancy and lactation
Pregnancy category: B
Lactation: not safe for nursing infants
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Lamisil AT topical (terbinafine topical)
Metabolism: liver
Excretion: urine
Mechanism of action
Inhibits squalene epoxidase, reducing cell membrane ergosterol synthesis